Carl-Gustaf Johansson
Chairman at IMED AB
Profile
Carl-Gustaf Johansson currently works at IMED AB, as Chairman and EffeRX, Inc., as Director.
Mr. Johansson also formerly worked at Astra AB, as President & Chief Executive Officer, AstraZeneca Pharmaceuticals LP, as President & Chief Executive Officer, Astra Pharmaceuticals AB, as President & Chief Executive Officer, AstraZeneca R&D Boston, Inc., as Chief Executive Officer, Astra USA, Inc., as Chief Executive Officer in 1999, Newron Sweden AB, as Chairman, Avaris AB, as Chairman, EffRx, Inc., as Director, EffRx Pharmaceuticals SA, as Director, and AstraZeneca PLC, as Executive Vice President.
Carl-Gustaf Johansson active positions
| Companies | Position | Start |
|---|---|---|
| EffeRX, Inc. | Director/Board Member | 04/08/2009 |
IMED AB
 IMED AB Drugstore ChainsRetail Trade IMED AB is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies. | Chairman | 26/11/2009 |
Former positions of Carl-Gustaf Johansson
| Companies | Position | End |
|---|---|---|
EffRx, Inc.
 EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co. | Director/Board Member | 10/06/2011 |
| Astra USA, Inc. | President | 01/01/1999 |
AstraZeneca Pharmaceuticals LP
 AstraZeneca Pharmaceuticals LP Pharmaceuticals: MajorHealth Technology AstraZeneca Pharmaceuticals LP develops, manufactures and markets prescription pharmaceutical drugs. It sells products related to gastrointestinal, cardiovascular, neuroscience, respiratory and oncology infections. The company was founded in 1953 and is headquartered in Wilmington, DE. | Chief Executive Officer | - |
| Astra Pharmaceuticals AB | Chief Executive Officer | - |
Astra AB
 Astra AB Pharmaceuticals: MajorHealth Technology Astra AB used to manufacture and market cardiovascular preparations, local anesthetics, anti-infective agents and medical-care equipment. The firm's products were Pulmicort, Xylocaine, Marcaine, EMLA and Naropin. It had operations in Scandinavia, Europe, North & South America, Australia, New Zealand, Africa and Asia. The company was headquartered in Södertälje, Sweden. | Chief Executive Officer | - |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| Private companies | 11 |
|---|---|
Astra AB
Astra AB Pharmaceuticals: MajorHealth Technology Astra AB used to manufacture and market cardiovascular preparations, local anesthetics, anti-infective agents and medical-care equipment. The firm's products were Pulmicort, Xylocaine, Marcaine, EMLA and Naropin. It had operations in Scandinavia, Europe, North & South America, Australia, New Zealand, Africa and Asia. The company was headquartered in Södertälje, Sweden. | Health Technology |
EffRx, Inc.
EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co. | Health Technology |
EffRx Pharmaceuticals SA
 EffRx Pharmaceuticals SA Pharmaceuticals: OtherHealth Technology EffRx Pharmaceuticals SA manufactures and distributes specialty pharmaceutical products. The firm's focus areas include metabolic bone disease, oncology supportive care, pediatric medication, and medical support to companies in life cycle management. It also engages in licensing agreements and distribution and commercialization partnerships. The company was founded by Christer Ros?n in 1998 and is headquartered in Freienbach, Switzerland. | Health Technology |
Newron Sweden AB
 Newron Sweden AB Pharmaceuticals: MajorHealth Technology Newron Sweden AB is a biopharmaceutical company engaged in the development of novel therapies for the treatment of disorders of the central nervous systems. The company was founded by Jonas Cristopher Frisen and Ann Marie Janson in 1998 and is headquartered in Stockholm, Sweden. | Health Technology |
AstraZeneca Pharmaceuticals LP
AstraZeneca Pharmaceuticals LP Pharmaceuticals: MajorHealth Technology AstraZeneca Pharmaceuticals LP develops, manufactures and markets prescription pharmaceutical drugs. It sells products related to gastrointestinal, cardiovascular, neuroscience, respiratory and oncology infections. The company was founded in 1953 and is headquartered in Wilmington, DE. | Health Technology |
| Astra Pharmaceuticals AB | |
AstraZeneca R&D Boston, Inc.
 AstraZeneca R&D Boston, Inc. Pharmaceuticals: MajorHealth Technology AstraZeneca R&D Boston, Inc. develops, manufactures and markets prescription pharmaceutical drugs. The company is headquartered in Cambridge, MA. | Health Technology |
| Astra USA, Inc. | |
IMED AB
IMED AB Drugstore ChainsRetail Trade IMED AB is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies. | Retail Trade |
Avaris AB
 Avaris AB Miscellaneous Commercial ServicesCommercial Services Avaris was founded in 2001 by research teams at the Karolinska Institute and Karolinska Innovations AB. The company is based on four proprietary technology platforms within cell and gene therapy. Avaris drives the research development and commercialization of new therapies in close collaboration with the founders, research teams, and strategic partners. The company is well positioned in cell and gene therapy field for chronic infections, cancer and inherited diseases. Avaris vision is to become the number one supplier of individualized cell and gene therapy treatments in northern Europe. In order to reach this goal it is exploring possibilities to acquire, or in license cell therapy technologies that complement the in house growth. Avaris is also open to partnering possibilities. | Commercial Services |
| EffeRX, Inc. |
- Stock Market
- Insiders
- Carl-Gustaf Johansson
